Patents by Inventor Dave S. B. Hoon

Dave S. B. Hoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11160542
    Abstract: A biomaterial collection device can include a wire that includes a functional member including a proximal end, a distal end, a first flat surface and a second flat surface opposing the first surface. The functional member can be configured to fit within a body lumen. The functional member can include binding elements configured to bind circulating biomolecules and cells. The functional member can include curved portions that form revolutions around the longitudinal axis of the device.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 2, 2021
    Assignee: Haimachek, Inc.
    Inventor: Dave S. B. Hoon
  • Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • Patent number: 9567640
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 14, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9556491
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: January 31, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9410206
    Abstract: Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 9, 2016
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Laurent Lessard
  • Publication number: 20130345144
    Abstract: Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 26, 2013
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Naoyuki Umetani
  • Patent number: 8288099
    Abstract: The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: October 16, 2012
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Michiel de Maat
  • Publication number: 20120088683
    Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
    Type: Application
    Filed: October 2, 2011
    Publication date: April 12, 2012
    Applicant: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Patent number: 8039218
    Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: October 18, 2011
    Assignee: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Publication number: 20110207136
    Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and ?-HCG.
    Type: Application
    Filed: January 12, 2011
    Publication date: August 25, 2011
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Hiroya Takeuchi
  • Publication number: 20110171240
    Abstract: The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin ?4 gene. Also disclosed are methods for treating subjects so identified.
    Type: Application
    Filed: December 30, 2010
    Publication date: July 14, 2011
    Inventors: Dave S. B. Hoon, Farin Amersi
  • Publication number: 20110171660
    Abstract: The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin ?4 gene. Also disclosed are methods for treating subjects so identified.
    Type: Application
    Filed: December 30, 2010
    Publication date: July 14, 2011
    Inventors: Dave S. B. Hoon, Farin Amersi
  • Patent number: 7943319
    Abstract: The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 17, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Norihiko Narita, Atsushi Tanemura
  • Patent number: 7910295
    Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and ?-HCG.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: March 22, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Hiroya Takeuchi
  • Patent number: 7897336
    Abstract: The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: March 1, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Bret Taback
  • Patent number: 7888033
    Abstract: The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed are a method of analyzing the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a pancreatic cancer cell, and a method of inhibiting the methylation of an ID4 gene promoter or enhancing the expression of an ID4 gene by contacting a pancreatic cancer cell with a compound that decreases the methylation level of an ID4 gene promoter or increases the expression level of an ID4 gene in the cell.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 15, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Naoyuki Umetani
  • Patent number: 7851161
    Abstract: The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 14, 2010
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Michiel de Maat
  • Patent number: 7829283
    Abstract: Methods for diagnosis, prognosis, and treatment of cancer based on the methylation status of the ER-? gene promoter are disclosed. Methylation of the ER-? gene promoter is indicative of cancer and unfavorable prognosis. The cancer can be treated with a demethylation agent.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: November 9, 2010
    Assignee: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Patent number: 7718364
    Abstract: A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: May 18, 2010
    Assignees: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Bret Taback
  • Publication number: 20100003689
    Abstract: The invention relates to methods for predicting the outcome of rectal cancer and stratifying a rectal cancer treatment according to the level of DNA methylation at MINT 1, 3, 12, or 17. Also disclosed is a method of detecting rectal adenoma or malignancy based on the level of DNA methylation at MINT 2, 3, or 31.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 7, 2010
    Applicant: John Wayne Cancer Institute
    Inventors: Dave S. B. HOON, Michiel F.G. de Maat